|
1
|
Ueno M, Muto T, Oya M, Ota H, Azekura K
and Yamaguchi T: Multiple primary cancer: An experience at the
Cancer Institute Hospital with special reference to colorectal
cancer. Int J Clin Oncol. 8:162–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Demandante CG, Troyer DA and Miles TP:
Multiple primary malignant neoplasms: Case report and a
comprehensive review of the literature. Am J Clin Oncol. 26:79–83.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jones AS, Morar P, Phillips DE, Field JK,
Husband D and Helliwell TR: Second primary tumours in patients with
head and neck squamous cell carcinoma. Cancer. 75:1343–1353. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aydiner A, Karadeniz A, Uygun K, Tas S,
Tas F, Disci R and Topuz E: Multiple primary neoplasms at a single
institution: Differences between synchronous and metachronous
neoplasms. Am J Clin Oncol. 23:364–370. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ries LA, Eisner MP, Kosary CL, Hankey BF,
Miller BA and Clegg L: SEER Cancer Statistics Review. 1975–2000.
National Cancer Institute; Bethesda, MD: 2003
|
|
6
|
Jiao F, Hu H and Wang LW: Quadruple
primary malignancy patient with survival time more than 20 years.
World J Gastroenterol. 19:1498–1501. 2003. View Article : Google Scholar
|
|
7
|
Jones P: Five separate malignancies in one
patient. Br Med J. 1:15331976. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shankar PS: Case report. Five primary
cancers in one patient Postgrad Med. 61:281–282. 1977.PubMed/NCBI
|
|
9
|
Liu LY, Sheng SH, Zhang ZY and Xu JH: A
case of matrix-producing carcinoma of the breast with micoglandular
adenosis and review of literature. Int J Clin Exp Pathol.
8:8568–8572. 2015.PubMed/NCBI
|
|
10
|
Ye Y, Neil AL, Wills KE and Venn AJ:
Temporal trends in the risk of developing multiple primary cancers:
A systematic review. BMC Cancer. 16:8492016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baigrie RJ: Seven different primary
cancers in a single patient. A case report and review of multiple
primary malignant neoplasia. Eur J Surg Oncol. 17:81–83.
1991.PubMed/NCBI
|
|
12
|
Curtis RE, Freedman DM, Ron E, Ries LAG,
Hacker DG, Edwards BK, Tucker MA and Fraumeni JF Jr: New
malignancies among cancer survivors: SEER cancer registries,
1973–2000. National Cancer Institute; Bethesda, MD, NIH Publ.: No.
05-5302. 2006
|
|
13
|
Linet MS, Slovis TL, Miller DL, Kleinerman
R, Lee C, Rajaraman P and Berrington de Gonzalez A: Cancer risks
associated with external radiation from diagnostic imaging
procedures. CA Cancer J Clin. 62:75–100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meyerhardt JA, Mangu PB, Flynn PJ, Korde
L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL,
et al: Follow-up care, surveillance protocol, and secondary
prevention measures for survivors of colorectal cancer: American
society of clinical oncology clinical practice guideline
endorsement. J Clin Oncol. 31:4465–4470. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mathews JD, Forsythe AV, Brady Z, Butler
MW, Goergen SK, Byrnes GB, Giles GG, Wallace AB, Anderson PR,
Guiver TA, et al: Cancer risk in 680000 people exposed to computed
tomography scans in childhood or adolescence: Data linkage study of
11 million Australians. BMJ. 346:f23602013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim C, Bi X, Pan D, Chen Y, Carling T, Ma
S, Udelsman R and Zhang Y: The risk of second cancers after
diagnosis of primary thyroid cancer is elevated in thyroid
microcarcinomas. Thyroid. 23:575–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morgan DJ, Dhruva SS, Wright SM and
Korenstein D: Update on medical practices that should be questioned
in 2015. JAMA Intern Med. 175:1960–1964. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matesich SM and Shapiro CL: Second cancer
after breast cancer treatment. Semin Oncol. 30:740–748. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Williams-Brown MY, Salih SM, Xu X,
Veenstra TD, Saeed M, Theiler SK, Diaz-Arrastila CR and Salama SA:
The effect of tamoxifen and raloxifene on estrogen metabolism and
endometrial cancer risk. J Steroid Biochem Mol Biol. 126:78–86.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Breuss JM, Gillett N, Lu L, Sheppard D and
Pytela R: Restricted distribution of integrin beta 6 mRNA in
primate epithelial tissue. J Histochem Cytochem. 41:1521–1527.
1999. View Article : Google Scholar
|
|
22
|
Breuss JM, Gallo J, DeLisser HM,
Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K,
Landers DV, Carpenter W, et al: Expression of the beta 6 integrin
subunit in development, neoplasia and tissue repair suggests a role
in epithelial remodeling. J Cell Sci. 108:2241–2251.
1995.PubMed/NCBI
|
|
23
|
Bates RC, Bellovin DI, Brown C, Maynard E,
Wu B, Kawakatsu H, Sheppard D, Oettgen P and Mercurio AM:
Transcriptional activation of integrin beta 6 during the
epithelial-mesenchymal transition defines a novel prognostic
indicator of aggressive colon carcinoma. J Clin Invest.
115:339–347. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W,
Wang JY, Niu WB, Liu EY, Mi YT and Niu J: Integrin alpha v beta 6
acts as a prognostic indicator in gastric carcinoma. Clin Ongol.
20:61–66. 2008. View Article : Google Scholar
|
|
25
|
Niu J, Gu X, Turton J, Meldrum C, Howard
EW and Agrez M: Integrin-mediated signalling of gelatinase B
secretion in colon cancer cells. Biochem Biophys Res Commun.
249:287–291. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Agrez M, Gu XH, Turton J, Meldrum C, Niu
J, Antalis T and Howard EW: The alpha v beta 6 integrin induces
gelatinase B secretion in colon cancer cells. Int J Cancer.
81:90–97. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT,
Wang JS, Chen R and Niu J: Integrin alpha v beta 6 mediates the
potential for colon cancer cells to colonize in and metastasize to
the liver. Cancer Sci. 99:879–887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Wang J, Niu W, Liu E, Wang J, Peng
C, Lin P, Wang B, Khan AQ, Gao H, et al: The β6-integrin-ERK/MAP
kinase pathway contributes to chemo resistance in colon cancer.
Cancer Lett. 328:325–334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT,
Wang JS, Chen R and Niu J: Integrin alpha v beta 6 mediates the
potential for colon cancer cells to colonize in and metastasize to
the liver. Cancer Sci. 99:879–887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu S, Liang B, Gao H, Zhang F, Wang B,
Dong X and Niu J: Integrin αvβ6 as a novel marker for diagnosis and
metastatic potential of thyroid carcinoma. Head Neck Oncol.
5:72013.
|
|
31
|
Koide N, Adachi W, Koike S, Watanabe H,
Yazawa K and Amano J: Synchronous gastric tumors associated with
esophageal cancer: A retrospective study of twenty-four patients.
Am J Gastroenterol. 93:758–762. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chai W, Gong FY, Zhang WL, Wen Y and Cui
LF: Multiple primary cancer in the female genital system. Medicine.
96:472017. View Article : Google Scholar
|
